Teva and Takeda fill in details on new Japan generics JV

Generic powerhouse Teva Pharmaceutical Industries ($TEVA) and Takeda said last year that they were working a deal to sell generics in Japan, a piece of the market expected to grow significantly as the government pushes off-patent drugs. Now the two have released details about how they will do that. The companies said they will shift to the new company products that include Blopress for hypertension, Takepron for peptic ulcers, and Basen for Type 2 diabetes. In a statement, they said those drugs generated sales in 2014 of ¥125 billion ($1.03 billion) in fiscal 2014. Read more from FiercePharmaAsia

Suggested Articles

The cleaning procedures are so poor at a Zydus Cadila plant in India that the FDA says a sampling found 10 different cross-contaminated products.

Oklahoma politicians contend J&J should be on the line for future abatement costs even after a $572 million verdict, but J&J sees things differently.

Abbott helmsman Miles White, who oversaw the spinoffs of AbbVie and Hospira, will step down as CEO after 21 years at the top job.